Immediate Therapeutics is a clinical-stage biotechnology company focused on protecting vulnerable tissue during the earliest moments of acute ischemic injury.
The company was founded to address a fundamental gap in emergency care: while current standards of treatment prioritize restoring blood flow, they do not address the rapid metabolic failure that occurs in the minutes immediately following ischemic onset—when tissue remains salvageable but unprotected.
Immediate Therapeutics is developing IMT-358, a novel metabolic stabilization therapy designed for use at the point of care in time-critical settings, including pre-hospital and early in-hospital environments.
Immediate Therapeutics is built around timing, not organs.
Unlike traditional approaches that focus on reperfusion after injury is underway, our strategy is centered on early metabolic protection during the initial phase of ischemic stress.
Key differentiators include:
Time-zero intervention: Designed for use as early as possible in the care pathway
Metabolic focus: Addresses cellular energy failure rather than downstream injury
Emergency compatibility: Aligned with real-world emergency workflows
Platform potential: Applicable across multiple acute ischemic contexts
This is not a cardiology company in the traditional sense — it is a company focused on time-critical tissue protection.
Operating Philosophy
Immediate Therapeutics is built to:
- Engage early and constructively with regulators
- Design trials that reflect real-world emergency care
- Prioritize operational rigor over speed for its own sake
- Maintain scientific and clinical integrity in all communications
Our approach reflects the seriousness of the patients, clinicians, and systems we aim to serve.
A Platform for Early Ischemic Intervention
Immediate Therapeutics is a privately held company advancing IMT-358 toward a pivotal Phase 3 program under an FDA Special Protocol Assessment.
The company is supported by experienced leadership, clinical advisors, and scientific collaborators, and is actively preparing for the next phase of development and execution.
